Nutter Represents WuXi Biologics in Purchase of 7-Acre Parcel in WorcesterPrint PDF
Nutter served as legal counsel to WuXi Biologics, a global company with leading open-access biologics technology platforms, in its purchase of an approximately seven-acre parcel of land at The Reactory, a 46-acre, master-planned biomanufacturing campus in Worcester, MA. The Nutter deal team was led by Mike Scott and Chris Papavasiliou in the firm’s Real Estate Department, and included Brent McDonald, John Lerner, and Brian Beaulieu.
WuXi Biologics will be the first company located in the Worcester Biomanufacturing Park, where it plans to develop a $60 million state-of-the-art biologics clinical and commercial manufacturing facility. The approximately 107,000-square-foot, two-story facility will be operational in 2022 and create 150 new jobs. Please click for more information on the transaction.
Nutter’s Real Estate Department provides expertise, both nationally and regionally, on the wide range of legal challenges surrounding all types of real estate, including the most complex transactions and developments. The team has broad experience covering real estate transactional and finance work, as well as related entitlement, land use, and environmental matters. Owners, operators, lenders, developers, property managers, institutional investors, governmental authorities and quasi-governmental organizations, hospitals and other health care providers, educational institutions, and other not-for-profit entities frequently turn to Nutter for legal advice on their real estate needs.
Nutter is a Boston-based law firm that provides legal counsel to industry-leading companies, early stage entrepreneurs, institutions, foundations, and families, across the country and around the world. The firm’s business and finance, intellectual property, litigation, real estate and land use, labor and employment, tax, and trusts and estates practices are national in scope. The firm was co-founded in 1879 by former U.S. Supreme Court Justice Louis D. Brandeis, before his appointment to the Court. For more information, please visit www.nutter.com and follow the firm on LinkedIn.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. As of December 31, 2019, there were a total of 250 integrated projects, including 121 projects in pre-clinical development stage, 112 projects in early-phase (phase I and II) clinical development, 16 projects in late-phase (phase III) development, and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore exceeding 280,000 liters by 2022, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.